Myelodysplastic Syndromes (MDS)

MDS/MPN-RS-T Justified Inclusion as a Unique Disease Entity?

Read more about MDS/MPN-RS-T Justified Inclusion as a Unique Disease Entity?

Myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) is a disease entity characterized by anemia anemia: (uh-NEE-mee-uh) A condition in which there is a shortage of

Therapy-related Myelodysplastic Syndromes Deserve Specific Diagnostic Sub-Classification and Risk-Stratification-An Approach to Classification of Patients With t-MDS

Read more about Therapy-related Myelodysplastic Syndromes Deserve Specific Diagnostic Sub-Classification and Risk-Stratification-An Approach to Classification of Patients With t-MDS

In the current World Health Organization (WHO)-classification, therapy-related myelodysplastic syndromes myelodysplastic syndromes:

Cyclosporine Enhances the Sensitivity to Lenalidomide in MDS/AML in Vitro

Read more about Cyclosporine Enhances the Sensitivity to Lenalidomide in MDS/AML in Vitro

Our previous study revealed that expression of G protein-coupled receptor 68 (GPR68) was upregulated in MDSL cells, a cell line representing myelodysplastic syndromes

Genetics of Progression From MDS to Secondary Leukemia

Read more about Genetics of Progression From MDS to Secondary Leukemia

Our understanding of the genetics of acute myeloid leukemia acute myeloid leukemia: (uh-KYOOT my-uh-LOYD loo-KEE-mee-uh) A cancer of the bloo

Secondary Myelodysplastic Syndrome and Leukemia in Acquired Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria

Read more about Secondary Myelodysplastic Syndrome and Leukemia in Acquired Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria

Acquired aplastic anemia aplastic anemia: (ay-PLASS-tik uh-NEE_mee-uh) A rare and serious condition in which the bone marrow fails to make enough blood cells - red blood cells,

External Resources

Read more about External Resources

This is a list of many resources that may be helpful to patients and their families dealing with a bone marrow failure bone marrow failure: A

MDS Toolkit

Read more about MDS Toolkit

Myelodysplastic Syndromes

Krisstina Gowin, DO

Institution

University of Arizona

Physician Status

accepting new patients

Primary Disease Area of Focus

Acute Myeloid Leukemia (AML)

Aplastic Anemia

Myelodysplastic Syndromes (MDS)

Myeloproliferative Neoplasms (MPN)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Pure Red Cell Aplasia (PRCA)

About

Krisstina Gowin, DO is an Assistant Professor of Medicine at the University of Arizona. Dr. Gowin graduated from Chicago College of Osteopathic Medicine in 2009, where she received a merit scholarship and recognition from the American Women’s Medical Association for outstanding academic achievement. She completed internal medicine residency at University of Southern California, hematology and medical oncology training at Mayo Clinic in Arizona, fellowship training in integrative medicine at the University of Arizona. She is board certified in medical oncology, internal medicine and hematology

Read more about Krisstina Gowin, DO

Pevonedistat plus azacitidine may increase survival for myelodysplastic syndrome, AML

Original Publication Date

June 15, 2020

Article Source

External Web Content

Pevonedistat plus azacitidine increased overall survival, event-free survival and response rates compared with azacytidine alone in higher-risk myelodysplastic syndromes and low-blast acute myeloid leukemia, according to data presented at ASCO. (continued at link)

Srinivasa Reddy Sanikommu, MD

Institution

Levine Cancer Institute - Morehead

Physician Status

accepting new patients

Primary Disease Area of Focus

Acute Myeloid Leukemia (AML)

Aplastic Anemia

Myelodysplastic Syndromes (MDS)

Myeloproliferative Neoplasms (MPN)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Read more about Srinivasa Reddy Sanikommu, MD

Subscribe to Myelodysplastic Syndromes (MDS)

Your Gift Today Changes Lives

Myelodysplastic Syndromes (MDS)

MDS/MPN-RS-T Justified Inclusion as a Unique Disease Entity?

Therapy-related Myelodysplastic Syndromes Deserve Specific Diagnostic Sub-Classification and Risk-Stratification-An Approach to Classification of Patients With t-MDS

Cyclosporine Enhances the Sensitivity to Lenalidomide in MDS/AML in Vitro

Genetics of Progression From MDS to Secondary Leukemia

Secondary Myelodysplastic Syndrome and Leukemia in Acquired Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria

External Resources

MDS Toolkit

Krisstina Gowin, DO

Pevonedistat plus azacitidine may increase survival for myelodysplastic syndrome, AML

Srinivasa Reddy Sanikommu, MD

Website Feedback

Patient Helpline